Method and devices for treating atrial fibrillation by mass ablation
Apparatus and method for ablating target tissue including a non-linear area of tissue in the left atrium of a patient. The method can include selecting an ablation apparatus having an ablator with a tissue engagement section, penetrating a chest cavity of the patient, and identifying the target tissue. The method can also include positioning the ablation apparatus adjacent to the target tissue so that the tissue engagement section can transfer ablation energy to the target tissue. The method can further include energizing the tissue engagement section with ablation energy in order to create a footprint on the non-linear area of tissue in the left atrium and to reduce an overall mass of excitable tissue in the left atrium.
This application claims the benefit of the filing date of U.S. Provisional Patent Application No. 60/571,182 filed on May 14, 2004, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTIONThe present invention relates to tools and procedures generally and relates more particularly to the use of ablation to reduce the mass of excitable tissue of the left atrium to prevent and treat atrial fibrillation or other medical conditions.
BACKGROUNDFocal triggers initiating atrial fibrillation are thought to frequently arise from the pulmonary veins and their ostia. Surgeons have used the technique of modifying the substrate of the heart in these areas to prevent the propagation of the arrhythmia. In some patients with chronic atrial fibrillation, the Cox/MAZE III procedure has been employed. This procedure controls propagation of the depolarization wavefronts in the right and left atria by means of surgical incisions through the walls of the right and left atria. The incisions create blind or dead end conduction pathways, which prevent re-entrant atrial tachycardias from occurring.
While the Cox/MAZE procedure is successful in treating atrial fibrillation, the procedure is quite complex and is currently practiced by only a few very skilled cardiac surgeons in conjunction with other open-heart procedures. The procedure also is quite traumatic to the heart, as in essence, the right and left atria are cut into pieces and sewed back together, to define lines of lesion across which the depolarization wavefronts will not propagate. Still today, the Cox/MAZE procedure is done with traditional cut and sew techniques.
The market is demanding quicker, safer and less invasive approaches. As a result, there has been much recent research and evaluation of mechanisms to encircle and isolate the pulmonary veins and replicate the incisions of the MAE operation. Companies are developing ablation techniques that heat (or cool) or chemically destroy the underlying tissue along these lines.
It has been suggested that procedures similar to the MAZE procedure could be instead, performed by means of electrosurgical ablation, for example, by applying radio frequency energy to internal or external surfaces of the atria to create lesions across which the depolarization wavefronts will not propagate. Such procedures are disclosed in U.S. Pat. No. 5,895,417, issued to Pomeranz, et al. (“the Pomeranz '417 patent”); U.S. Pat. No. 5,575,766, issued to Swartz, et al. (“the Swartz '766 patent”); U.S. Pat. No. 6,032,077, issued to Pomeranz (“the Pomeranz '077 patent”); U.S. Pat. No. 6,142,994, issued to Swanson, et al. (“the Swanson '994 patent”); and U.S. Pat. No. 5,871,523, issued to Fleischman, et al. (“the Fleischman '523 patent”), all incorporated herein by reference in their entireties.
The Pomeranz '417 patent discloses an apparatus for ablating tissue by making linear lesions within the chamber of a patient's heart by application of a plurality of spaced electrodes along an elongate member. The Schwartz '766 patent discloses a process for treating atrial arrhythmia by creating discrete ablation tracks within both the left and right atrium. The Pomeranz '077 patent discloses an ablation catheter that is electrically connected to tissue to be ablated by a foam on the electrodes that is soaked in saline. The foam in the Pomeranz '077 patent acts as a conductive fluid to allow energy from the electrode to ablate the contacted tissue. The Swanson '994 patent discloses a surgical method and apparatus for positioning an element in the body of a patient for diagnosis or therapy. The apparatus in the Swanson '994 patent may be a catheter or a probe having a shaft with a lumen extending there through. The Fleischman '523 patent discloses a helically-wound emitter on an element with a insulating sheath movable over the emitter.
Various types of electrophysiology devices are used for ablating tissue. Typically, such devices include a conductive tip or blade that serves as one electrode in an electrical circuit that is completed via a grounding electrode coupled to the patient. The contact point is small or linear to create lesions to form linear tracks of ablated tissue. A power source creates high levels of electrical energy between the two electrodes causing the tissue to heat to a sufficient level to denature proteins within the tissue and cause cell death. In order for such procedures to be effective, it is desirable that the electrosurgically-created lesions are continuous along their length and extend completely through the tissue of the heart.
Manufacturers have developed catheters that have a linear array of electrodes along a long axis (e.g., the Amazr, MECCA, and Revelation catheters). The surgeon positions the catheter and electrodes in contact with the tissue and either individually or sequentially applies energy to each electrode. Additionally, catheters that incorporate an electrode that is energized and moves along its length have been proposed, such as the Flex-10 from AFx, Inc., of 47929 Fremont Aye, Fremont, Calif. 94538.
Surgeons have also been able to create linear lesions on the heart using applications of the same techniques. For example, Kottkamp, et. al. in an article entitled “Intraoperative Radio Frequency Ablation of Chronic Atrial Fibrillation: A Left Atrial Curative Approach by Elimination of Anatomic ‘Anchor’ Reentrant Circuits,” Journal of Cardiovascular Electrophysiology, 10:772-780 (1999), describe a hand-held device that creates as series of spot or short (less than 1 cm) linear lesions. Other investigators have used long, linear unipolar probes to create somewhat longer lesions. Still others have used multi-electrode linear catheters, similar to those described above to create a series of ablations that net a linear lesion.
The focus of most investigators has been to isolate the pulmonary veins. There is growing research that suggests this may not be necessary in the prevention and cure of atrial fibrillation, as discussed in the article by G. Stabile, P. Turco, V. La Rocca, P. Nocerino, E. Stabile, and A. Dc Simone entitled “Is Pulmonary Vein Isolation Necessary for Curing Atrial Fibrillation?,” Circulation, 108:657-660 (2003). Rather than focusing on only isolating the pulmonary veins, reduction in the overall volume of excitable tissue in the left atrium is sufficient to prevent atrial fibrillation. The general concept is to ablate a large enough nonlinear area of the left atrium to prevent re-entrant waves and the propagation of atrial fibrillation.
SUMMARY OF THE INVENTIONSome embodiments of the invention provide a method of ablating target tissue including a non-linear area of tissue in the left atrium of a patient. The method can include selecting an ablation apparatus having an ablator or ablation member with a tissue engagement section, penetrating a chest cavity of the patient, and identifying the target tissue. The method can also include positioning the ablation apparatus adjacent to the target tissue so that the tissue engagement section can transfer ablation energy to the target tissue. The method can further include energizing the tissue engagement section with ablation energy in order to create a footprint on the non-linear area of tissue in the left atrium and to reduce an overall mass of excitable tissue in the left atrium.
In some embodiments, an ablation apparatus can include an insertion tool having a proximal end, a distal end, and a lumen. The ablation apparatus can include an ablator or ablation member having a conductor and a tissue engagement portion. The conductor can include a source end extending from the proximal end of the insertion tool and a delivery end coupled to the tissue engagement portion. The ablator can be removably inserted in the lumen. The ablation apparatus can also include an energy source connected to the conductor. The insertion tool can be inserted into a patient so that the distal end is adjacent the target tissue. The conductor can urge the ablator out of the lumen to engage the target tissue. Energy can be conducted from the energy source to the ablator to create a footprint on the target tissue to reduce an overall mass of excitable tissue.
BRIEF DESCRIPTION OF THE DRAWINGS
Before any embodiments of the invention are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limited. The use of “including,” “comprising” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. The terms “mounted,” “connected” and “coupled” are used broadly and encompass both direct and indirect mounting, connecting and coupling. Further, “connected” and “coupled” are not restricted to physical or mechanical connections or couplings, and can include electrical connections or couplings, whether direct or indirect.
Some embodiments of the invention provide a method and apparatus for reducing the mass of the viable tissue (e.g., by rendering the mass of tissue non-contractile, non-viable, or unable to propagate an action potential) in the left atrium of the heart to prevent or cure atrial fibrillation. Some embodiments of the invention can include preventing reentry of depolarizing wavefront signals by ablating a large area of the left atrium. Furthermore, some embodiments of the invention can substantially prevent the sustenance of atrial fibrillation.
Embodiments of the invention can provide an ablation apparatus used to conduct ablating energy to a locale of contacted or non-contacted and possibly surrounding tissue with the intent to ablate an entire area, while not harming neighboring tissue. The ablation apparatus can include an electrode having a footprint of a dimension designed to cover a predetermined region of tissue in the left atrium.
According to some embodiments of the invention, an ablation apparatus can be used to ablate a non-linear area of the tissue in the left atrium en masse. This method can be performed by endocardial positioning of an ablation device in the left atrium either via a trans-atrial septal puncture or retrograde through the arterial system. Alternatively, embodiments of the invention can provide a method of ablating tissue in the left atrium in a predefined area by inserting an ablating apparatus using an epicardial approach with access to the posterior left atrium through the pericardial space, either by a sub-xiphoid or inter-costal incision.
Some embodiments of the invention provide a method of ablating tissue using a large footprint ablation electrode for the control, prevention, and cure of atrial fibrillation. The method can include ablating a predefined area of tissue in the left atrium, while protecting other areas of the heart, lungs, and esophagus using directional energy delivery, insulation, or standoffs to space the ablation apparatus from protected areas. The method of ablating the heart tissue can include using a trans-venous catheter from the inside of the heart to deliver the ablation apparatus. Location and imaging techniques such as echogram, sonogram, magnetic resonance imaging, ultrasound, X-ray, sensors or transmitters on the ablation device, or other mapping technology can allow for proper placement to minimize damage to surrounding tissue.
Some embodiments of the invention include a locatable ablation apparatus having a predefined footprint that can be delivered through an incision in the chest wall in order to ablate by trans-myocardial engagement with a bipolar electrode. The ablation apparatus can use any of suitable method and/or procedure with electro-surgical devices or other types of ablation devices (e.g., thermal ablation, micro-wave ablation, cryogenic ablation, ultrasound ablation, etc.) to ablate tissue in the left atrium to reduce the mass of excitable tissue therein.
The apparatuses and methods of some embodiments of the invention are designed to reduce the overall excitable mass of the left atrium and to reduce or cure atrial fibrillation (AF). Some embodiments of the invention use radio frequency energy to create heat and ablate an area of tissue. However, other embodiments of the invention may include additional or alternative energy sources, such as microwave, cryogenic, ultrasound, laser, thermal, etc. Also, some embodiments of the invention can be used for creating ablation lesions in other areas of the heart, such as the ventricles.
As shown in
Proper positioning of the ablator 43 on the targeted tissue 15 can be performed by any suitable means, such as direct visualization, fluoroscopic X-ray visualization, ultrasound positron emission tomography, fluoroscopy, intra-cardiac echo, trans-esophageal echo, magnetic resonance imaging, computerized tomography, or by endoscopic imaging. As shown in
The ablator 34 can include a tissue engagement section 60 (as shown in
As shown in
In some embodiments, the balloon 58 can include a conducting surface that acts as a tissue engagement section 60. A collapsed balloon 58 can be inserted into the left atrium 12 or into the pericardial space surrounding the epicardial surface of the target tissue 15. In one embodiment, the balloon 58 can then be inflated with saline from the inflation source 64 and oriented such that a thermally-transmissive, tissue engagement section 60 of the balloon 58 can be positioned against the posterior left atrium and an insulated portion of the balloon 58 can be positioned against the anterior left atrium. The saline can be heated by electrical current supplied by power source 46 to a temperature between 50 degrees Celsius and 85 degrees Celsius, and in some embodiments, between 55 degrees Celsius and 65 degrees Celsius. At these temperatures, the cells in the target area 15 generally die without collagen shrinkage. Alternatively, the balloon 58 can be cooled with cryogenic technology to freeze the atrial tissue and ablate the target tissue 15. Generally, temperatures for cryogenic therapy must be less than negative 20 degrees Celsius to negative 40 degrees Celsius.
The ablator 43 can be delivered to the desired location in the patient using the insertion tool 32, such as a catheter 70, as shown in
The circular ablator 43 can be used epicardially by insertion within the pericardial space adjacent the posterior left atrium. In one embodiment, the circular ablator 43 can alternatively include an uncoiling spiral configuration. The uncoiling spiral can be positioned through a sheath 32, and when advanced beyond the sheath 32, can uncoil to take the desired shape. Pre-formed shape memory or superelastic alloys, such as NiTi, can be used to ensure that the spiral uncoils into the desired shape.
In another embodiment, two circular ablators 43 can be used in a bipolar arrangement. One ablator 43 can be on the external surface 14 of the target tissue 15 and another ablator 43 can be positioned on the internal surface 24 of the target tissue 15 in the left atrium 12. The bipolar circular ablator 43 can also be positioned using an uncoiling spiral configuration. The uncoiling spiral can be positioned through a sheath 32, and when advanced beyond the sheath 32, can uncoil to take the desired shape. Pre-formed shape memory or superelastic alloys, such as NiTi, can be used to ensure that the spiral uncoils into the desired shape.
In some embodiments, the ablator 43 (e.g., an ablation energy transmitting member having one or more ablating elements) may be remote from the target tissue 15. For example, ultrasound energy may be focused remotely on the target tissue 15, causing ablation of the target tissue 15, while passing without ablating through non-targeted tissue located between the targeted tissue and ablator 43. The location of the energy focus on the target tissue 15 can be moved throughout the region to be ablated by steering a focal point about a non-linear area to be ablated. A steering mechanism can be manual (e.g., by physically moving an ultrasound transducer relative to the tissue) or electrical (e.g., by using phased arrays of ultrasound transducers or by otherwise modifying the ultrasound focal zone).
Some embodiments of the invention are effective at terminating atrial fibrillation, yet can be performed more safely than some conventional methods. Some embodiments of the invention can perform ablations more quickly than some conventional methods. Some embodiments of the invention can also be used to amputate, ligate, staple, etc. the left atrial appendage (LAA) of the heart—a major source of clots and strokes in the population. Some embodiments of the invention result in less trauma to the patient and less chance of accidentally damaging the heart and surrounding structures. Some embodiments of the invention can minimize the size of the incision required to insert the ablation apparatus 30 and/or the ablator 43 through the chest wall. Some embodiments of the invention can eliminate the need for contiguous, linear lesions to treat atrial fibrillation. Some embodiments of the invention can allow the surgeon to create lesions in the heart from the epicardial surface of the beating heart. Some embodiments of the invention can be practiced via transvenous catheters from the inside of the heart.
Various additional features and advantages of the invention are set forth in the following claims.
Claims
1. A method of ablating target tissue including a non-linear area of tissue in a left atrium of a patient, the method comprising:
- selecting an ablation apparatus having an ablator with a tissue engagement section;
- penetrating a chest cavity of the patient;
- identifying the target tissue;
- positioning the ablation apparatus adjacent to the target tissue so that the tissue engagement section can transfer ablation energy to the target tissue; and
- energizing the tissue engagement section with ablation energy in order to create a footprint on the non-linear area of tissue in the left atrium and to reduce an overall mass of excitable tissue in the left atrium.
2. The method of claim 1 and further comprising choosing an ablation apparatus using at least one of radio frequency energy, thermal energy, cryogenic energy, chemical energy, pharmacological energy, ultrasound energy, microwave energy, laser energy, and radiation energy.
3. The method of claim 1 and further comprising choosing an ablation apparatus including at least one of a balloon, a mesh, a patch, a rolled electrode, a fan, a bipolar electrode, a wiper, and a crystal transmitter.
4. The method of claim 1 and further comprising penetrating the chest cavity by entering through at least one of a sub-xiphoid incision, a sub-costal incision, a sternotomy, a thoracotomy, and a trans-venous puncture.
5. The method of claim 1 and further comprising identifying the target tissue using at least one of direct visualization, X-ray, ultrasound, magnetic resonance imaging, positron emission tomography, computerized tomography, fluoroscopy, endoscopic observation, intra cardiac echo, and transesophageal echo.
6. The method of claim 1 and further comprising placing the ablation apparatus adjacent the outside of the left atrium by an epicardial approach.
7. The method of claim 1 and further comprising placing the ablation apparatus adjacent the inside of the left atrium by an endocardial approach.
8. The method of claim 1 and further comprising placing the ablation apparatus adjacent the left atrium by a transesophageal approach.
9. The method of claim 8 and further comprising energizing the tissue engagement section with ultrasound energy.
10. The method of claim 9 and further comprising focusing the ultrasound energy on the target tissue.
11. The method of claim 1 and further comprising transferring energy to a portion of the ablation apparatus at the tissue engagement section.
12. The method of claim 1 and further comprising:
- removably placing the ablation apparatus in a delivery end of an insertion tool;
- positioning the insertion tool into the patient through an incision;
- directing the delivery end to a location adjacent the target tissue;
- removing the ablation apparatus from the insertion tool; and
- adjusting the ablation apparatus to bring the tissue engagement section in contact with the target tissue.
13. The method of claim 1 and further comprising affixing the tissue engagement section to the target tissue by at least one of a bio-adhesive, a vacuum, an inflatable balloon, a mechanical deflection, a magnetic field, a shape memory alloy, and a superelastic alloy.
14. The method of claim 1 and further comprising providing an insulator in the ablation apparatus to prevent damage to tissue adjacent the target tissue.
15. An ablation apparatus for ablating target tissue of a patient, the ablation apparatus comprising:
- an insertion tool having a proximal end, a distal end, and a lumen;
- an ablator including a conductor and a tissue engagement portion, the conductor having a source end extending from the proximal end of the insertion tool and a delivery end coupled to the tissue engagement portion, the ablator removably inserted in the lumen; and
- an energy source connected to the conductor;
- the insertion tool being inserted into a patient so that the distal end is adjacent the target tissue, the conductor urging the ablator out of the lumen to engage the target tissue;
- energy being conducted from the energy source to the ablator to create a footprint on the target tissue to reduce an overall mass of excitable tissue.
16. The ablation apparatus of claim 15 and further comprising a sensor connected to the ablator to sense the target tissue.
17. The ablation apparatus of claim 15 and further comprising a mapping tool to visualize the tissue engagement portion of the ablator.
18. The ablation apparatus of claim 15 wherein the insertion tool includes a catheter.
19. The ablation apparatus of claim 15 wherein the ablator includes a patch removably attachable to the target tissue, the patch including at least one of an adhesive patch, a tongue patch, a circular patch, a balloon patch, a suction patch, a chemical release patch, a rolled patch, a carbon patch, and a webbed patch.
20. The ablation apparatus of claim 15 wherein the ablator includes a skirt that can suction to the target tissue, the skirt receiving fluid for conducting the energy to the target tissue.
21. The ablation apparatus of claim 20 wherein the fluid is electrically conductive.
22. The ablation apparatus of claim 20 wherein the fluid is caustic.
23. The ablation apparatus of claim 20 wherein the fluid is thermally conductive.
24. The ablation apparatus of claim 15 wherein the ablator includes a balloon, the balloon being inflatable to occupy a cavity in the patient adjacent to the target tissue, the balloon being removably stored in the distal end of the insertion tool wherein the balloon is inflated causing the balloon to emerge from the insertion tool, and the balloon being positionable to cause the tissue engagement portion to bear against the target tissue.
25. The ablation apparatus of claim 15 wherein the ablator includes a chemical delivery system.
26. The ablation apparatus of claim 25 wherein the chemical delivery system includes a delivery method of at least one of diffusion, iontophoresis, mechanical injection, needle-less injection, and controlled slow-release delivery.
27. The ablation apparatus of claim 15 wherein the ablator includes a skirt and an adhesive tongue inside the skirt, the tongue moveable within the skirt to engage the target tissue, the skirt affixing the ablator to the target tissue by a vacuum.
28. The ablation apparatus of claim 15 wherein the tissue engagement portion includes a first bipolar tissue electrode and a second bipolar tissue electrode, wherein the first bipolar tissue electrode is applied to the interior of the left atrium endocardially, wherein the second bipolar tissue electrode is applied to the exterior of the left atrium epicardially, each of the first and second bipolar tissue electrodes connected to the energy source, energy being applied from the energy source to conduct from the first bipolar tissue electrode to the second bipolar tissue electrode to render a mass of left atrium tissue located between the first and second bipolar tissue electrodes at least one of non-contractile, non-viable, and unable to propagate an action potential.
Type: Application
Filed: May 13, 2005
Publication Date: Jan 12, 2006
Inventors: David Francischelli (Brooklyn Park, MN), Mark Stewart (Brooklyn Park, MN), James Skarda (Lake Elmo, MN)
Application Number: 11/128,786
International Classification: A61B 18/18 (20060101); A61B 18/14 (20060101);